A phase 1 study of ZKN-013 in healthy volunteers
Latest Information Update: 28 Feb 2025
At a glance
- Drugs ZKN 013 (Primary)
- Indications Epidermolysis bullosa; Familial adenomatous polyposis
- Focus Adverse reactions
Most Recent Events
- 24 Feb 2025 Status changed from planning to recruiting.
- 15 Mar 2024 New trial record